MLICM
PRCT icon

Metropolitan Life Insurance Company (MetLife)’s Procept Biorobotics PRCT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,153
Closed -$106K – 1595
2024
Q1 		$106K Sell
2,153
-161
-7% -$7.66K ﹤0.01% 1014
2023
Q4 		$97K Buy
2,314
+139
+6% +$4.73K ﹤0.01% 1102
2023
Q3 		$71.4K Buy
2,175
+186
+9% +$6.34K ﹤0.01% 1199
2023
Q2 		$70.3K Buy
1,989
+570
+40% +$18.8K ﹤0.01% 1217
2023
Q1 		$40.3K Sell
1,419
-182
-11% -$6.42K ﹤0.01% 1520
2022
Q4 		$66.5K Hold
1,601
– – ﹤0.01% 1306
2022
Q3 		$66.4K Hold
1,601
– – ﹤0.01% 1271
2022
Q2 		$52.3K Buy
1,601
+1,014
+173% +$36.9K ﹤0.01% 1478
2022
Q1 		$20.5K Buy
+587
New +$14.1K ﹤0.01% 2082

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PRCT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Procept Biorobotics (PRCT) in Q2 2024, closing a stake of 2,153 shares — an estimated $106K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PRCT in Q1 2022 and held it in 9 quarters. The position peaked at $106K in Q1 2024. 201 funds tracked by Wall St. Rank hold PRCT as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Procept Biorobotics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,153 Procept Biorobotics shares in Q2 2024, an estimated $106K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Procept Biorobotics in Q1 2022 and held it in 9 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Procept Biorobotics position peaked at $106K in Q1 2024.
  • 201 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.